Coincide out the companies making headlines after the bell:
Energen surged myriad than 7 percent in after-hours trading after Diamondback Energy asserted it was acquiring the oil and gas company for about $9.2 billion, including debt, or $84.95 per allot. The acquisition price represents a 16.1 percent premium to Tuesday’s work out price of $73.14. The all-stock deal is expected to close by the end of the fourth place of this year. Diamondback’s stock, meanwhile, lost 7.3 percent.
Teva Pharmaceuticals ascension 1.2 percent after a regulatory filing showed Warren Buffett’s Berkshire Hathaway distended its position by 6.7 percent during the second quarter. Teva’s trade in later pared its gains. The filing also showed Berkshire strengthened its stake in Southwest Airlines and Delta Air Lines, which rose 1.18 percent and 1.86 percent, singly, in after-hours trading.
Lighting products company Cree slipped multitudinous than 1 percent after the bell as the company issued disappointing gross income guidance for its fiscal first quarter. The company said it expects sellings to range between $395 million and $415 million, below a FactSet guess of $416 million.
Shares of Agilent Technologies initially ticked 0.3 percent gamy after the bell upon the release of its fiscal third-quarter earnings. The circle reported a profit of 67 cents per share. Analysts polled by Reuters needed earnings per share of 63 cents. Revenue matched estimates at $1.2 billion. CEO Mike McMullen suggested Agilent’s results were driven by its China business as well as toughness in “the global pharma and chemical & energy end markets.” The stock later canceled its slight gains and traded 0.2 percent lower, however.
Improvement: Diamondback Energy is buying Energen in an all-stock deal. A previous view of this story misstated the type of deal.